The Latest
COUR Pharmaceuticals Doses First Patient in Phase 1b/2a Clinical Trial Evaluating CNP-106 in Generalized Myasthenia Gravis
Skip to primary navigation
Skip to main content
Skip to footer
COUR Pharmaceuticals
Our Company
Leadership
Board of Directors
Advisors
Partners
Contact
Our Technology
Pipeline
Our Clinical Trials
CNP-106 Myasthenia Gravis
Publications & Media
Press Releases
Publications
Careers
Tim Walbert
Former Chairman, President and Chief Executive Officer, Horizon Therapeutics;
Sr. Advisor, Amgen
